• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Zagazig University Medical Journal
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 27 (2021)
Issue Issue 2
Issue Issue 1
Volume Volume 26 (2020)
Volume Volume 25 (2019)
Volume Volume 24 (2018)
Volume Volume 23 (2017)
Volume Volume 22 (2016)
Volume Volume 21 (2015)
Volume Volume 20 (2014)
Volume Volume 19 (2013)
Elsayed mostafa, M., esmaiel, A., nossir, W., abdelfattah, M. (2021). Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia. Zagazig University Medical Journal, 27(2), 334-342. doi: 10.21608/zumj.2019.14882.1415
Mona Gamal Elsayed mostafa; anwer ezzat esmaiel; wael sabry nossir; mostafa taha abdelfattah. "Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia". Zagazig University Medical Journal, 27, 2, 2021, 334-342. doi: 10.21608/zumj.2019.14882.1415
Elsayed mostafa, M., esmaiel, A., nossir, W., abdelfattah, M. (2021). 'Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia', Zagazig University Medical Journal, 27(2), pp. 334-342. doi: 10.21608/zumj.2019.14882.1415
Elsayed mostafa, M., esmaiel, A., nossir, W., abdelfattah, M. Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia. Zagazig University Medical Journal, 2021; 27(2): 334-342. doi: 10.21608/zumj.2019.14882.1415

Clinical response and patient's tolerance of vaginal versus oral bromocriptine in women who suffers hyperprolactinaemia

Article 231, Volume 27, Issue 2, March 2021, Page 334-342  XML PDF (590.52 K)
Document Type: Original Article
DOI: 10.21608/zumj.2019.14882.1415
Authors
Mona Gamal Elsayed mostafa email 1; anwer ezzat esmaiel2; wael sabry nossir3; mostafa taha abdelfattah4
1Obstetrics and gynecology, faculty of medicine, Zagazig university, Egypt
2obstetric and gynecology. faculty of medicine. zagazig university. zagazig. egypt
3obstetric and gynecology. faculty of medicine. zagazig univeristy. mitghamer. egypt
4obstetric and gynecology. faculty of medicine. zagazig universty. mitghamer. egypt
Abstract
Hyperprolactinaemia is areal challenge for gynecologist and endocrinologists ,bromocriptine was used for treating hyperprolactinaemia ,bromocriptine associated with many side effect this study aimed to compare clinical response , side effects and tolerability of vaginal versus oral bromocriptine for treatment of hyperprolactinemia
Patients and methods: Non randomized controlled clinical trial at the out-patient Clinic of Obstetrics and Gynecology,Zagazig University and Zifta general hospital (ministry of health). This study included 87 patients who suffered hyperprolactinaemia .Patients divided into 3 groups:Group A included 29 patients who used bromocriptine 2.5mg tablets vaginally once daily for one month .Group B included 29 patients who administrated bromocriptine 2.5mg vaginal suppositories once daily for one month. Group C included 29 patients who received bromocriptine 2.5mg tablet orally twice daily for one month.Serum prolactin was measured before and after therapy in all cases.
Results:Bromocriptine was effective in decreasing level of prolactin whether used orally or vaginally. Vaginal bromocriptine suppositories application was associated with minimal side effect both local and general .Nausea was the most frequent side effect with oral tablets ,while excessive vaginal discharge and dyspareunia was the most occurring local side effect. Most side effect in three groups occur within the first 10 day after starting therapy.
Conclusions: Bromocriptine is avery effective drug in treating hyperprolactinaemia, restoration of normal ovulation ,improvement of mastalgia and galactorrhea .Based on our results vaginal bromocriptine suppositories is associated with minimal local and systemic side effect when compared with bromocriptine tablets when used orally or vaginally.
Key words: Hyperprolactinaemia ,Bromocriptine, oral, vagina.
Keywords
Hyperprolactinaemia; Oral; vaginal; bromocriptine
Main Subjects
Obstetrics & Gynaecology
Statistics
Article View: 139
PDF Download: 26
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.